These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 8607397)

  • 1. A randomized comparison of flecainide versus verapamil in paroxysmal supraventricular tachycardia. The Flecainide Multicenter Investigators Group.
    Dorian P; Naccarelli GV; Coumel P; Hohnloser SH; Maser MJ
    Am J Cardiol; 1996 Jan; 77(3):89A-95A. PubMed ID: 8607397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety and utility of flecainide acetate in the routine care of patients with supraventricular tachyarrhythmias: results of a multicenter trial. The Flecainide Supraventricular Tachycardia Study Group.
    Hopson JR; Buxton AE; Rinkenberger RL; Nademanee K; Heilman JM; Kienzle MG
    Am J Cardiol; 1996 Jan; 77(3):72A-82A. PubMed ID: 8607395
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group.
    Chimienti M; Cullen MT; Casadei G
    Eur Heart J; 1995 Dec; 16(12):1943-51. PubMed ID: 8682031
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of long-term oral flecainide acetate in patients with responsive supraventricular tachycardia.
    Hellestrand KJ
    Am J Cardiol; 1996 Jan; 77(3):83A-88A. PubMed ID: 8607396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Flecainide acetate prevents recurrence of symptomatic paroxysmal supraventricular tachycardia. The Flecainide Supraventricular Tachycardia Study Group.
    Henthorn RW; Waldo AL; Anderson JL; Gilbert EM; Alpert BL; Bhandari AK; Hawkinson RW; Pritchett EL
    Circulation; 1991 Jan; 83(1):119-25. PubMed ID: 1898640
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correlation of symptoms with occurrence of paroxysmal supraventricular tachycardia or atrial fibrillation: a transtelephonic monitoring study. The Flecainide Supraventricular Tachycardia Study Group.
    Bhandari AK; Anderson JL; Gilbert EM; Alpert BL; Henthorn RW; Waldo AL; Cullen MT; Hawkinson RW; Pritchett EL
    Am Heart J; 1992 Aug; 124(2):381-6. PubMed ID: 1636582
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term safety and efficacy of flecainide in the treatment of supraventricular tachyarrhythmias: the United States experience. The Flecainide Supraventricular Tachyarrhythmia Investigators.
    Anderson JL
    Am J Cardiol; 1992 Aug; 70(5):11A-17A; discussion 17A-18A. PubMed ID: 1509993
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group.
    Naccarelli GV; Dorian P; Hohnloser SH; Coumel P
    Am J Cardiol; 1996 Jan; 77(3):53A-59A. PubMed ID: 8607392
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group.
    Aliot E; Denjoy I
    Am J Cardiol; 1996 Jan; 77(3):66A-71A. PubMed ID: 8607394
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized, placebo-controlled trial of propafenone in the prophylaxis of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation. UK Propafenone PSVT Study Group.
    Circulation; 1995 Nov; 92(9):2550-7. PubMed ID: 7586356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Flecainide as first-line treatment for supraventricular tachycardia in newborns.
    Ferlini M; Colli AM; Bonanomi C; Salvini L; Galli MA; Salice P; Ravaglia R; Centola M; Danzi GB
    J Cardiovasc Med (Hagerstown); 2009 May; 10(5):372-5. PubMed ID: 19300276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Role of a "bystander" concealed accessory pathway in the response to verapamil and flecainide treatment in a patient with nodal reentry tachycardia].
    Matteucci C; Busi G
    G Ital Cardiol; 1996 Apr; 26(4):419-25. PubMed ID: 8707026
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Flecainide single oral dose for management of paroxysmal supraventricular tachycardia in children and young adults.
    Musto B; Cavallaro C; Musto A; D'Onofrio A; Belli A; De Vincentis L
    Am Heart J; 1992 Jul; 124(1):110-5. PubMed ID: 1615792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flecainide acetate treatment of paroxysmal supraventricular tachycardia and paroxysmal atrial fibrillation: dose-response studies. The Flecainide Supraventricular Tachycardia Study Group.
    Pritchett EL; DaTorre SD; Platt ML; McCarville SE; Hougham AJ
    J Am Coll Cardiol; 1991 Feb; 17(2):297-303. PubMed ID: 1899432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A randomized, multicenter trial to compare the safety and efficacy of adenosine versus verapamil for termination of paroxysmal supraventricular tachycardia].
    Cheng KA;
    Zhonghua Nei Ke Za Zhi; 2003 Nov; 42(11):773-6. PubMed ID: 14636464
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Electrophysiological effects and clinical efficacy of flecainide in childhood patients with supraventricular reciprocating paroxysmal tachycardia].
    Musto B; D'Onofrio A; Cavallaro C; Musto A; Della Gatta O; Marsico F
    G Ital Cardiol; 1987 May; 17(5):444-9. PubMed ID: 3115857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Adenosine for paroxysmal supraventricular tachycardia: dose ranging and comparison with verapamil. Assessment in placebo-controlled, multicenter trials. The Adenosine for PSVT Study Group.
    DiMarco JP; Miles W; Akhtar M; Milstein S; Sharma AD; Platia E; McGovern B; Scheinman MM; Govier WC
    Ann Intern Med; 1990 Jul; 113(2):104-10. PubMed ID: 2193560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Flecainide acetate for paroxysmal supraventricular tachyarrhythmias. The Flecainide Supraventricular Tachycardia Study Group.
    Anderson JL; Platt ML; Guarnieri T; Fox TL; Maser MJ; Pritchett EL
    Am J Cardiol; 1994 Sep; 74(6):578-84. PubMed ID: 8074041
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of out-of-hospital self-administered single-dose oral drug treatment in the management of infrequent, well-tolerated paroxysmal supraventricular tachycardia.
    Alboni P; Tomasi C; Menozzi C; Bottoni N; Paparella N; Fucà G; Brignole M; Cappato R
    J Am Coll Cardiol; 2001 Feb; 37(2):548-53. PubMed ID: 11216977
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Electrophysiologic effects and therapeutic efficacy of intravenous flecainide for termination of paroxysmal supraventricular tachycardia.
    Gambhir DS; Bhargava M; Arora R; Khalilullah M
    Indian Heart J; 1995; 47(3):237-43. PubMed ID: 7558090
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.